Neisseria meningitidis News and Research

RSS

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

FDA approves Sanofi Pasteur's meningococcal vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra, to include a two-dose schedule for infants and children 9 months through 23 months of age.

25 Apr 2011

Avenir team discovers how Neisseria meningitidis disseminates into bloodstream

Although, in the majority of cases, the localized presence of Neisseria meningitidis in the throat has no consequence, it can sometimes lead to meningitis or septicaemia. The seriousness of these two infections is driving researchers from around the world to improve their understanding of the mode of operation of this bacterium, which, once it leaves its favourite location becomes extremely dangerous.

18 Feb 2011

First evidence of human DNA fragment in bacterial genome

If a human cell and a bacterial cell met at a speed-dating event, they would never be expected to exchange phone numbers, much less genetic material. In more scientific terms, a direct transfer of DNA has never been recorded from humans to bacteria.

14 Feb 2011

MenAfriVac to help health workers eliminate meningococcal A epidemics

The West African nation of Burkina Faso today became the first country to begin a nationwide campaign to introduce a new meningitis vaccine that promises to rid the entire region of the primary cause of epidemic meningitis. The first vaccine designed specifically for Africa, MenAfriVac is expected to help health workers eliminate meningococcal A epidemics in the 25 countries of the meningitis belt, stretching from Senegal in the west to Ethiopia in the east.

6 Dec 2010

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Researchers from the Boston University School of Medicine (BUSM) have demonstrated that commensal species of the genus Neisseriae are low inducers of human airway epithelial cell responses as compared to the pathogenic species.

24 Nov 2010

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

26 Aug 2010

Physician recommends vaccination for Meningitis before children start school

Freshmen all across the nation have begun packing in preparation for college. Along with their laptops, notebooks, pens and binders, there is one more essential item they need - a meningitis vaccination. "If a student hasn't gotten a meningitis vaccination, they absolutely should get one before they start school," said Dr. Michael Koller, associate professor of medicine, division of general internal medicine, Loyola University Chicago Stritch School of Medicine, Maywood. "Meningitis is not a common disease but it can be tragic."

18 Aug 2010

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

8 Jun 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Swedish study opens new potential for combating resistant bacteria

Neisseria meningitidis, the meningococcus, is a bacterium that can cause diseases with high fatality rates, and there has therefore been considerable concern that, like other bacteria, it might become resistant to antibiotics. But now a study from örebro University and örebro University Hospital in Sweden shows that there has not been any increase in resistant meningococci in Sweden over the last 15 years. According to researcher Sara Thulin Hedberg, the reason for this may be that it is not especially advantageous for bacteria to develop resistance.

5 Jan 2010

Break through in the treatment of bacterial meningitis

It can take just hours after the symptoms appear for someone to die from bacterial meningitis. Now, after years of research, experts at The University of Nottingham have finally discovered how the deadly meningococcal bacteria is able to break through the body's natural defence mechanism and attack the brain.

13 May 2009

Meningitis bacteria dress up as human cells to evade our immune system

The way in which bacteria that cause bacterial meningitis mimic human cells to evade the body's innate immune system has been revealed by researchers at the University of Oxford and Imperial College London.

20 Feb 2009

Fractional dose of scarce meningitis vaccine may be effective in outbreak control

A partial dose of a commonly used vaccine against meningitis may be as effective as a full dose, according to new research published December 2 in the open-access journal PLoS Neglected Tropical Diseases.

1 Dec 2008

Australian scientists discover a way to stop meningitis

Australian scientists have discovered a bacteria which could stop meningitis - the scientists at the University of Western Australia believe their discovery will help researchers understand how the meningitis bacteria infects cells and could lead to the prevention of infections such as meningitis.

25 Nov 2008

African countries commit to new meningitis vaccine

Health ministers from countries of the African meningitis belt today committed themselves to introduce a highly promising candidate meningitis vaccine. The vaccine is designed to prevent periodic epidemics of the deadly disease in these countries.

4 Sep 2008

Sanofi Pasteur receives FDA approval of Menactra meningococcal vaccine for children

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include children 2 years through 10 years of age.

22 Oct 2007

FDA expands approved age range for Menactra, bacterial meningitis vaccine

The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine, to include children ages 2 to 10 years.

19 Oct 2007

Study looks at sepsis and purpura in children

While survival rates for sepsis have increased over the past two decades, children under four and those in adolescence remain highly susceptible to the condition.

18 Oct 2007